Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study

20251 citationsJournal Articlehybrid Open Access

Authors

Yuichi Hori · Toho University

T Wada · Senju Pharmaceutical (Japan)

Abstract

SJP-0132 showed generally dose-dependent efficacy and safety. Based on safety and treatment benefits with SJP-0132 0.3% in the overall population and in subgroups, this dose was considered optimal for further development.

Topics & Keywords

Ocular Surface and Contact Lens Connexins and lens biology Retinal Diseases and Treatments

Publication Details

Published in: American Journal of Ophthalmology

Volume 283, pp. 163-175

DOI: 10.1016/j.ajo.2025.11.036

Field-Weighted Citation Impact: 1.94

Command Palette

Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study

Authors

Abstract

Topics & Keywords

Publication Details